Biktarvy in international markets
Gilead Sciences (GILD) had launched Biktarvy in 19 European markets by the end of the first quarter. According to the first-quarter earnings conference call, Biktarvy was launched in Germany in June and France in October. The drug has already emerged as the number one prescribed HIV regimen in these two markets, both for treatment-naïve patients and for those switching from other regimens. The company now expects to launch Biktarvy in Italy and the United Kingdom by mid-2019.
In March, Gilead Sciences secured approval from Japan’s MHLW (Ministry of Health, Labour and Welfare) for Biktarvy in the HIV-1 indication. The drug was launched in the Japanese market in the first quarter.
Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
Descovy-based drug sales
In the first quarter, Gilead Sciences reported worldwide HIV product sales of $2.61 billion, a YoY rise of 43%. Genvoya reported sales of $1.02 billion, a YoY decline of 6.19%, while Odefsey reported sales of $397 million, a YoY rise of 16.08%.
Top prescribed regimens
According to the company’s first-quarter earnings investor presentation, four products in Gilead Sciences’ HIV franchise (Biktarvy, Genvoya, Stribild, and Atriple) are among the top five prescribed regimens for treatment-naïve HIV patients in the US. Additionally, Genvoya and Biktarvy are also the leading two HIV regimens, while Atripla and Odefsey are the fourth and fifth leading regimens for all HIV patients in the US.
According to the company’s first-quarter earnings investor presentation, four products in Gilead Sciences’ HIV franchise such as Biktarvy, Genvoya, Odefsey, and Truvada are among the top five prescribed regimens for treatment-naïve HIV patients in the five major European countries of France, Italy, Spain, Germany, and the UK. Genvoya, Complera/Eviplera, Odefsey, and Atripla are the second, third, fourth, and fifth leading regimen for all HIV patients in the five European countries.